Any current/future capex/capital investment/strategic investment?

The company plans capital investment in both R&D and manufacturing infrastructure, either through acquisitions or organic expansion in India. Focus on expanding front-end presence with products in strong markets like Europe (Italy, Germany, France, UK, Spain). Exploring growth opportunities via mergers and acquisitions, especially in emerging markets including India and Europe. Intends to build new manufacturing sites for CDMO focused on complex products. Current debt levels are manageable; free cash flow generation expected to support organic growth and acquisitions. Considering leveraging ba

Future growth expectations in sales/revenue/volumes?

The company targets maintaining a revenue mix of approximately 55% formulation and 45% API/CDMO, with both segments expected to show similar growth, supported by CDMO compensating slower growth in regular APIs. Over the next 3-5 years, the Animal Health formulation business is expected to grow significantly, particularly in the companion animal segment driven by increasing pet ownership and genericization. CDMO business is projected to grow substantially, particularly after 2-3 years, once commercial supply of lifecycle management products ramps up. Animal Health APIs are anticipated to grow v

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets a 15%-20% CAGR growth in EBITDA over the next 3-5 years, with occasional spikes due to acquisitions. Confident in sustaining 20% EBITDA margins, already achieving close to this level ahead of schedule. Expected EBITDA growth driven by synergies from recent merger, R&D product pipeline, and expanding Animal Health and CDMO segments. Anticipates steady topline and bottomline growth from a balanced revenue mix (~55% formulations and 45% API/CDMO). Free cash flow generation is strong, supporting organic growth and selective acquisitions without heavy CAPEX. EPS expected to impr

Any current/future new fundraising through debt or equity?

The company currently has a comfortable debt position, with debt around INR 200 crores, considered manageable. They expect to generate good free cash flow over the next 12-18 months, supporting growth without urgent need for external funding. There is no immediate plan for raising large amounts of debt or equity overnight; growth and investments will be paced. The company is open to leveraging the balance sheet for organic growth and selective acquisitions, potentially using debt or share swap in the long term. Additionally, there are warrants and remaining equity (around 25%) that the managem

IN US

Sale is live|00:00:00left today

Viyash Scientific LtdQ4 FY27Pharmaceuticals & Biotechnology

Viyash Scientific Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹255P/E: 69.7Market Cap: ₹8.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company targets maintaining a revenue mix of approximately 55% formulation and 45% API/CDMO, with both segments expected to show similar growth, supported by CDMO compensating slower growth in regular APIs.
→Over the next 3-5 years, the Animal Health formulation business is expected to grow significantly, particularly in the companion animal segment driven by increasing pet ownership and genericization.
→CDMO business is projected to grow substantially, particularly after 2-3 years, once commercial supply of lifecycle management products ramps up.
→Animal Health APIs are anticipated to grow very fast starting next year, backed by infrastructure and process improvements.
→The merged entity aims to achieve INR 4,000 crore revenue with consistent ~20% EBITDA margins by FY'27, leveraging organic growth, synergies, and potential acquisitions.
→Emerging markets like Southeast Asia and Africa are targeted for expansion, alongside strengthened presence in Europe and India.

Margin guidance

Category 3

→The company targets a 15%-20% CAGR growth in EBITDA over the next 3-5 years, with occasional spikes due to acquisitions.
→Confident in sustaining 20% EBITDA margins, already achieving close to this level ahead of schedule.
→Expected EBITDA growth driven by synergies from recent merger, R&D product pipeline, and expanding Animal Health and CDMO segments.
→Anticipates steady topline and bottomline growth from a balanced revenue mix (~55% formulations and 45% API/CDMO).
→Free cash flow generation is strong, supporting organic growth and selective acquisitions without heavy CAPEX.
→EPS expected to improve in line with EBITDA growth, benefiting from reduced debt and interest costs.
→Aiming for INR 4,000 crore revenue and 20% EBITDA margin by FY'27, comfortably on track based on current run rate.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company currently has a comfortable debt position, with debt around INR 200 crores, considered manageable.
→They expect to generate good free cash flow over the next 12-18 months, supporting growth without urgent need for external funding.
→There is no immediate plan for raising large amounts of debt or equity overnight; growth and investments will be paced.
→The company is open to leveraging the balance sheet for organic growth and selective acquisitions, potentially using debt or share swap in the long term.
→Additionally, there are warrants and remaining equity (around 25%) that the management plans to convert within 12 months, providing some additional capital.
→Overall, the focus is on sustainable, balanced growth without aggressive fundraising but with flexibility for future strategic opportunities.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Viyash Scientific Limited. However, the following points provide some context related to order flow and business outlook: - CDMO business saw timing-related variations in quarterly revenues; some contracts shifted sales and validation supplies to next quarters. - CDMO revenue for the year is expected around INR 70-90 crores, with new products and life cycle management projects expected to commercialize next year. - Growth areas such as Animal Health formulations and CDMO are showing increasing inquiries and RFQs, indicating a growing order pipeline. - The company expects steady expansion in animal health and API businesses, supported by regulatory approvals and new product launches over 18-24 months. - Integration synergies and network operations improvements are on track, supporting growth and operational efficiency. No direct numeric data about the order book or pending orders is provided.

Capex plans

Yes

→The company plans capital investment in both R&D and manufacturing infrastructure, either through acquisitions or organic expansion in India.
→Focus on expanding front-end presence with products in strong markets like Europe (Italy, Germany, France, UK, Spain).
→Exploring growth opportunities via mergers and acquisitions, especially in emerging markets including India and Europe.
→Intends to build new manufacturing sites for CDMO focused on complex products.
→Current debt levels are manageable; free cash flow generation expected to support organic growth and acquisitions.
→Considering leveraging balance sheet and potential share swaps for long-term sustainable growth.
→Investment to accelerate companion animal business, particularly in India and key European markets.
→Exploring supply chain strengthening and potential M&A in North America for Animal Health formulations.
→CAPEX is expected to be moderate for existing APIs but targeted for new growth areas like CDMO and companion animals.

How does Viyash Scientific Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Viyash Scientific Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Viyash Scientific Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio